Companies · Energy
Idaho Falls · ID, USA · Energy · founded 2018 · https://atomicalchemy.us
Diligence memoA one-page analyst read on Atomic Alchemy — recommendation, valuation, rhythm, risks.→Atomic Alchemy: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Atomic Alchemy is one of 69 Energy companies tracked from Idaho Falls, ID, USA, on record since 2018. By capital raised it ranks mid-pack (ahead of 54% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
We produce cancer-curing materials used in nuclear medicine.
Atomic Alchemy is building a bank of reactors to produce the nuclear material that goes into nuclear medicine. Radiopharmaceuticals are vitally important in biological tracers, diagnostic imaging, and cancer treatments. Currently, the world's supply of Molybdenum-99, the cornerstone of 80% of all nuclear medicine procedures, is sourced from just six government-run, scientific research reactors abroad. Five of these reactors are 45-65 years old and are quickly coming to the end of their operational life. This has cultivated a fragile and lengthy supply chain, at odds with the nature of radioactive material. This issue and its implications do not just effect molybdenum, but any other reactor-based isotope. Many promising cancer therapies are stuck in clinical trials, unable to secure enough material in a timely manner. Research doesn’t even happen because of the difficulty of sourcing any new isotopes. It doesn't have to be this way. Atomic Alchemy is working to solve this by building the world's first scalable radioisotope production facility. This facility will contain the world’s first privately-owned nuclear reactors dedicated to radioisotope production.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 69 companies in Energy. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 54% of sector peers (real $). Modeled value above 54% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Atomic Alchemy is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Apollo Atomics, Inc. | Energy | — | — | — | same sector |
| Aravolta | Energy | — | — | — | same sector |
| Archimede | Energy | Seed | $1.6M | $3.1M | same sector |
| Arnergy | Energy | Series A | $9.0M | $95.1M | same sector |
| Atomos Nuclear & Space Corp | Energy | Series B | $19.0M | $115.9M | same sector |
| Aurabeat | Energy | — | — | — | same sector |
| BlueLine Grid, Inc. | Energy | Series A | $10.3M | $25.9M | same sector |
| CellCube Energy Storage Systems Inc. | Energy | Pre-Seed | $539K | $6.3M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Duranium Reshoring critical metal production | — | — | — | 71% |
| AdvanCell Isotopes Pty Ltd | Biotechnology | Series A | $34.5M | 71% |
| 1849 bio Engineering microbes for miners to unlock billions in trapped metal | Biotech | — | — | 70% |
| Arizona Isotopes Science Research Corp. | Pharmaceuticals | Series C | $2.0B | 69% |
| Northwest Medical Isotopes, LLC | Healthtech | Seed | $96.4M | 69% |
| Atomicwork Inc. | Other Technology | Series B | $162.8M | 69% |
| Applied Atomics, Inc | Other Energy | Pre-Seed | $2.7M | 69% |
| Alchemy Nanotechnology-enabled coatings for automotive and defence sectors | Defense | — | — | 68% |
See where Atomic Alchemy sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Atomic Alchemy, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.